Status: Recruiting
HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML
A randomized，multicenter, open-label Phase III, clinical study is conducted to evaluate the clinical benefit Clifutinib in Chinese patients with relapsed/ refractory (R/R) FLT3-mutated AML as shown with overall survival compared to salvage chemotherapy, and also to investigate the efficacy of Clifutinib as assessed by CR/CRh rate in these subjects.
Participants needed: 324
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Sunshine Lake Pharma Co., Ltd.Updated: Apr 28, 2026Locations: 1
Eligibility criteria
Subject is ≥ 18 years of age at the time of obtaining informed consent. [+5]
Subject has received prior treatment with other FLT3 inhibitors [+4]